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Abstract 16 
Ovarian cancer (OC) is the deadliest gynecological malignancy. Most patients are diagnosed when 17 
they are already in the later stages of the disease. Earlier detection of OC dramatically improves 18 
the overall survival, but this is rarely achieved as there is a lack of clinically implemented 19 
biomarkers of early disease. Extracellular vesicles (EVs) are small cell-derived vesicles that have 20 
been extensively studied in recent years. They contribute to various aspects of cancer pathology, 21 
including tumour growth, angiogenesis and metastasis. EVs are released from all cell types and the 22 
macromolecular cargo they carry reflects the content of the cells from which they were derived. 23 
Cancer cells release EVs with altered cargo into biofluids, and so they represent an excellent 24 
potential source of novel biomarkers for the disease. In this review we describe the latest 25 
developments in EVs as potential biomarkers for earlier detection of OC. The field is still relatively 26 
young, but a number of studies have shown that EVs and the cargo they carry, including miRNAs 27 
and proteins, can be used to detect OC. They could also give insight into the stage of the disease 28 
and predict the likely therapeutic outcome. There remain a number of challenges to the use of EVs 29 
as biomarkers, but through ongoing research and innovation in this exciting field there is great 30 
potential for the development of diagnostic assays in the clinic that could improve patient 31 
outcome.  32 
 33 




Ovarian cancer (OC) is the 7th most commonly diagnosed cancer in women and the disease causes 39 
more than 150,000 deaths around the world each year, making it the deadliest gynecological 40 
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malignancy1, 2. The 5-year survival for OC patients is less than 50%3, and this is mostly due to the 41 
frequently late presentation of the disease (when the cancer has usually already spread to the 42 
peritoneal space) and the subsequent acquisition of therapeutic resistance during treatment3, 4.  43 
 44 
OC is a heterogeneous disease that is thought to originate from the epithelium of the ovaries5, 45 
though recent studies suggest that it may originate from cells shed from the fallopian tube6. It can 46 
be classified into two groups based on their distinct origin and histological characteristics5. The 47 
first group, originating from epithelial cells and known as epithelial ovarian cancer (EOC), accounts 48 
for almost 90% of all OC cases; this group can be further subdivided on the basis of histological 49 
morphology into serous (the majority of these are high-grade serous carcinoma [HGSC] and the 50 
rest are low-grade serous carcinoma [LGSC]), mucinous, endometrioid, and clear cell carcinomas7. 51 
The second group can originate from stromal and germ cells and include non-epithelial ovarian 52 
cancers that account for 10% of all OC cases8.   53 
 54 
The treatment of most patients with EOC comprises surgical debulking of the tumour mass 55 
followed by chemotherapy with platinum-based compounds such as carboplatin, cisplatin and 56 
oxaliplatin9. Successful debulking is the best correlate for subsequent survival10, 11. The treatment 57 
regime for EOC has changed little in the past few decades, with the addition of taxanes such as 58 
paclitaxel (which work by inhibition of microtubule function) being the only substantial change to 59 
the way in which EOCs are treated9. The report that the presence of tumor infiltrating 60 
lymphocytes is a good indicator of chemotherapy response and improved survival for OC implies a 61 
synergistic effect of immunotherapy and chemotherapy that may benefit some 62 
patients12.Immunotherapy for OC is still limited to clinical trials and only a low proportion of 63 
patients appear to benefit clinically, unlike immunotherapy treatment in melanoma which appears 64 
to be particularly successful13. There is therefore an urgent need for improved therapeutics for OC, 65 
but most importantly, an urgent need for the identification of improved high-sensitivity 66 
biomarkers to facilitate earlier detection of the disease and to monitor treatment response to 67 
standard and new therapy. 68 
 69 
Current biomarkers for ovarian cancer detection 70 
 71 
Almost 70% of OC cases are diagnosed at an advanced stage (III or IV) of the disease7,14. Early 72 
symptoms of OC, including back pain and digestive problems such as dyspepsia, are general and 73 
non-specific and are often related to benign conditions. It tends to be only later, once the less 74 
serious causes of symptoms have been eliminated and/or symptoms become more intense or 75 
severe, that the cancer is diagnosed15. Late diagnosis has a significant impact on prognosis; 76 
patients that are diagnosed in earlier stages have a five-year survival rate of >70% but this drops 77 
to <40% for those diagnosed in later stages4, 16. Transvaginal ultrasonography is an imaging-based 78 
approach, which could be used to identify earlier-stage disease, but it is invasive and trials have 79 
shown that as a screening tool it only has limited ability to reduce overall survival17-19. The inability 80 
to detect OC at an earlier stage reveals one of the biggest challenges in biomarker research: the 81 
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need of finding a highly sensitive, non-invasive screening method applicable to an asymptomatic 82 
population subject to develop OC during their life. 83 
 84 
 85 
Due to the high incidence and low survival rates, much research effort has been put into finding 86 
potential biomarkers for screening the disease. One of the first OC biomarkers identified was 87 
Cancer Antigen 125 (CA125), also known as MUC1620. CA125 is a high molecular weight trans-88 
membrane glycoprotein produced by coelomic epithelium, and thus far it is the most clinically 89 
utilised biomarker for monitoring the response to treatment and detecting disease recurrence21. 90 
When the treatment is successful the level of circulating CA125 can decrease, while increased 91 
levels are correlated with drug resistance and disease progression22. Although CA125 is used in the 92 
clinic, it has some limitations for the purpose of early detection, as it can be associated with both 93 
false positive and false negative results21. Non-epithelial ovarian tumours are not associated with 94 
increased levels of this mucin, and the various EOC subtypes produce different levels of CA125 95 
(levels are higher in HGSC compared to mucinous carcinoma, for example) 22-24. Some studies 96 
reported a higher correlation between the FIGO (International Federation of Gynecology and 97 
Obstetrics) staging and preoperative CA125 levels, whilst other studies suggest the correlation is 98 
less clear-cut23, 24. CA125 can also be detected in other physiological or pathological conditions 99 
leading to false positives; for example, it can be raised in the presence of other cancers including 100 
cervix, breast, colon and lung cancer25, and it can be altered in inflammatory pathologies26, during 101 
the menstrual cycle and in pregnancy27, 28. Moreover, in some cases of EOC the level of CA125 is 102 
not raised, and this is particularly true in the early stages of the disease when the presence of a 103 
biomarker would be most clinically useful29. CA125, therefore, does not represent the ideal 104 
biomarker for robust and diagnostic detection of early OC, and this is confirmed by clinical trials 105 
that reveal CA125 as a screening tool lead to only modest (if any) improvements in patient 106 
survival17, 18.  107 
 108 
Another biomarker that has been investigated is the Human Epididymis protein 4 (HE4)30. This is a 109 
small protein encoded by the WFDC2 (WAP Four-Disulfide Core Domain 2) gene and secreted by 110 
epithelial cells. HE4 is secreted by pulmonary epithelial cells, appears to be involved in sperm 111 
maturation, but is also highly expressed in the serum of OC patients when compared with healthy 112 
individuals30, 31 and it could be used for distinguishing OC from benign disease and to monitor 113 
treatment and recurrence32. Unfortunately, like CA125, HE4 has limitations as a biomarker; its 114 
expression has been associated with other conditions (especially with endometrial and lung cancer 115 
and cystic fibrosis) and different factors (including menstrual cycle, hormone treatment, age and 116 
smoking) can modify its expression, leading to false negatives and false positives28, 33.  .  117 
 118 
Greater predictive power could be achieved by combining different biomarkers. For example, the 119 
Risk for Ovarian Malignancy Algorithm combines CA125 and HE4 levels, leading to increases in 120 
both sensitivity and specificity and thus diagnostic accuracy35. The Risk of Malignancy Index 121 
combines CA125 levels, ultrasound results and menopausal status36. Another multivariate index 122 
assay known as OVA1 combines the results of measuring several different proteins alongside 123 
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CA12537. However, even these multiparametric tests suffer from false positives and negatives and 124 
the only definitive way to diagnose patients is during surgery, making these tests unsuitable for 125 
routinely screening OC in the female population. Further research is therefore needed to identify 126 
other potential biomarkers for earlier detection of OC.  127 
 128 
Extracellular Vesicles as cancer biomarkers 129 
 130 
Extracellular vesicles (EVs) are a heterogeneous group of cell-derived submicron vesicles 131 
surrounded by a lipid bilayer38. EVs can be broadly classified into three main types depending on 132 
the mechanisms of their biogenesis (Fig 1). Apoptotic bodies are considered to be larger EVs 133 
(>1000 nm in diameter, though smaller apoptotic vesicles can also be released) produced by 134 
apoptotic cells. Microvesicles (MVs) are a class of EVs produced by outward membrane budding of 135 
a cell with sizes ranging between 50 nm and 1 µm. Exosomes are small (30-150 nm in diameter) 136 
EVs produced when multivesicular bodies (MVBs) fuse with the plasma membrane leading to the 137 
release of the intraluminal vesicles (which, upon release, are then redefined as exosomes). 138 
Another class of EVs that is gaining attention in the tumour microenvironment is large oncosomes 139 
(LOs). LOs are a big class of EVs (3-4 um diameter), mostly originated from highly aggressive tumor 140 
cells and characterized by carrying a variety of oncogenic signals39, 40.  More recently, the group of 141 
David Lyden (Weill Cornell Medicine, New York, US) reported the identification of a new class of 142 
EVs, dubbed exomeres41. These particles, whose origin and mechanism of formation are still 143 
unknown, were found using asymmetric flow field-flow fractionation, are smaller than exosomes 144 
(<50nm) and were described as the most predominant particle secreted by cancer cells41. 145 
 146 
EVs were, until recently, thought to primarily perform the role of facilitating the release of 147 
unwanted cellular material42. While this may be one of their roles, we now know that they can 148 
serve a variety of functions43. They play significant roles in many biological processes, including 149 
angiogenesis and the immune response43. EVs are released from all cell types and they carry 150 
various types of cargo such as long nucleic acids (including mRNAs, lncRNAs and DNA), short 151 
nucleic acids (including miRNAs, vault RNAs, tRNAs and YRNAs), proteins, glycoproteins, 152 
carbohydrates, metabolites and lipids44, 45. Their biologically active cargo can be transferred into 153 
and used by recipient cells, leading to changes in the function of these cells46, 47. EVs are therefore 154 
an important part of the signaling dialogue that occurs between cells. Many of the EVs produced 155 
by cells can make their way into biofluids, including saliva, urine, cerebrospinal fluid, blood, 156 
semen, sweat and tears43. The molecular composition of EVs partially reflects the molecular 157 
landscape of the parental cell; given that this landscape can be altered in cancer, and that EVs can 158 
reach biofluids, these vesicles could serve as an easily accessible window into the state of a 159 
tumour48. Indeed, the very presence in biofluids of vesicles carrying cancer-related cargo could be 160 
a diagnostic indicator that a tumour is present.  161 
 162 
One approach that is often taken is to identify potential vesicular biomarkers in cancer patients is 163 
to initially use cultured cancer cell lines as a proxy. The cargo (miRNAs in particular) of EVs 164 
5  
released by cancer cell lines (compared to non-cancer cell lines) can be profiled using relatively 165 
unbiased techniques (such as microarrays or RNA-seq); transcripts that are identified as altered in 166 
cancer cell-derived EVs can then be measured in biofluids to see if they are also de-regulated in 167 
patients48. However, one potential issue is that, even though the foetal bovine serum that the 168 
cultured cells grow in has been pre-cleared of vesicles, it  still contains bovine-derived EVs carrying 169 
bovine miRNAs49. Directly testing biofluids using unbiased techniques may, therefore, be 170 
preferable as a method for identifying suitable EV biomarkers; however, working with EVs 171 
presents several technical challenges and there are a number of pre-analytical variables that affect 172 
the interpretation of the results of such experiments50, 51. Further work is also needed to establish 173 
the most reliable EV isolation strategy for the analysis of vesicular cargo in biofluids52.  174 
 175 
Despite these barriers, there is great excitement for the potential use of EVs as biomarkers to 176 
inform clinicians not just on the presence of tumours but also on the state of the tumour and its 177 
microenvironment48, 53. EVs can play an active role in the pathology of cancer, contributing to an 178 
increase in various undesirable phenotypes such as metastasis54, angiogenesis55 and drug 179 
resistance56. EVs released by stressed cells (including stress induced by the chemotherapeutic 180 
agent cisplatin) are able to induce a range of effects in neighbouring tumour cells, including 181 
increased invasion, bystander DNA damage and an adaptive response57-59. miRNAs are short non-182 
coding RNAs that can repress the expression of multiple genes, meaning that changes in their 183 
levels can lead to substantial phenotypic effects in a cell60. They are known to be involved in stress 184 
response61 and in mediating drug resistance in ovarian cancer62-64. miRNAs can also contribute to 185 
other cancer phenotypes, including migration and angiogenesis65. For these reasons, the miRNA 186 
content of EVs is of particular interest as a potential diagnostic in cancer48. A growing body of 187 
literature describes the early attempts to capitalize on EV cargo as a biomarker in a variety of 188 
cancer types. In the following section we will review current work investigating EVs as biomarkers 189 
in OC (Table 1).  190 
 191 
EVs as biomarkers in ovarian cancer 192 
 193 
Early forays into EV biomarker research in OC focused on simply counting the number of vesicles 194 
in circulation. Cancer cells produce more EVs when compared with normal cells, and this could be 195 
related to specific conditions in the tumour microenvironment66. The levels of circulating EVs were 196 
seen to be elevated in patients with EOC and these may correlate with disease stage67, 68.  197 
 198 
For the reasons described in the previous section , the detection of circulating vesicular RNA, 199 
particularly miRNA, could be used as a biomarker for OC. In addition, the RNA is protected from 200 
degradation whilst encapsulated in vesicles, and sensitive techniques can be used to amplify 201 
specific targets from relatively few copies of the nucleic acid, allowing a global view of the 202 
complex RNA landscape in these organelles69, 70. Many studies have analysed changes of miRNA 203 
levels in biofluids such as plasma or serum, but it is not always clear whether these changes 204 
represent free circulating miRNAs or those encapsulated in EVs; a more comprehensive review of 205 
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non-vesicular biomarkers in OC has been previously published71. Here we will focus on studies 206 
where EVs have been specifically investigated.  207 
 208 
In one early study it was shown that certain miRNAs (including miR-21, miR-141, miR-200a/b/c 209 
and miR-214) were more highly expressed in circulating EVs from OC compared to patients with 210 
benign disease68.  In another study the level of miR-200a/b/c and miR-373 were shown to be 211 
elevated in circulating EVs of EOC patients67. Correlations with stage and lymph node involvement 212 
were observed for miR-200a and miR-373, while lower overall survival correlated with levels of 213 
miR-200b/c67. EV miRNAs were measured in peritoneal or pleural effusions and the level of a 214 
combination of miRNAs was correlated with stage, progression free survival and overall survival72. 215 
An expression signature of eight miRNAs circulating in serum was also shown to distinguish 216 
healthy control from patients with OC73. Most of these miRNAs were shown to be vesicular when 217 
released by cell lines and xenografts73. In another study the levels of miR-21 were elevated in 218 
ovarian carcinoma EVs74. Pan et al showed that the levels of a number of miRNAs are altered in 219 
the plasma EVs of ovarian cancer patients. Interestingly, the levels of miR-200b correlated with 220 
CA125 and overall survival75. Urine could also be used as a source of diagnostic EVs. In one study 221 
the levels of miR-30a-5p were elevated in the urine of ovarian cancer patients, and this miRNA 222 
was shown to be found in EVs76.  223 
 224 
Proteins in EVs have also been investigated as potential OC biomarkers. Interestingly, CA125 has 225 
been identified in EVs and its vesicular levels were higher than freely circulating CA125 plasma 226 
levels at an earlier stage, suggesting that studying CA125 vesicular levels instead of freely 227 
circulating serum CA125 could be used to detect OC earlier73 .Another study demonstrated that 228 
the expression of Claudin 4 protein in EVs obtained from plasma of OC patients was positively 229 
correlated with tumor stage, with a sensitivity of 51% and specificity of 98%78. Furthermore, the 230 
dual measurement of CA125 and Claudin4 inside EVs could be used as a new combination 231 
biomarker, although further validation experiments need to be performed78. Patients with stage I 232 
EOC had a low level of circulating CA125 but high levels of Claudin 4, suggesting that relative levels 233 
of the two could be informative78. It has been shown that EVs derived from OC patients’ plasma 234 
contain increased levels of TGFβ1 and melanoma associated antigen 3 (MAGE3) compared with 235 
patients with benign disease, suggesting they could serve as potential biomarkers to distinguish 236 
between malignant and benign patients79. The levels of EpCAM, ADAM10 and EMMPRIN have also 237 
been shown to increase in EOC68, 80. Zhang et al developed a microfluidic device combined with 238 
ELISA to detect EVs; with this device they show that in a small cohort of patients the levels of 239 
EpCAM in plasma EVs from OC patients was higher compared to controls81. CD24 has been 240 
associated with poor prognosis in OC and it is highly enriched in EVs from ascitic fluid82, with most 241 
of the CD24 positive exosomes being secreted by tumour cells82. Combined measurement of 242 
vesicular EpCAM and CD24 can distinguish between patients that are responsive or non-243 
responsive to therapy83. Zhao et al developed a microfluidic device named ‘ExoSearch Chip’ to 244 
isolate serum exosomes that contain CA125, EpCAM and CD24. When EVs were isolated using 245 
antibodies against CA125 it was noted that patient samples contained a greater amount of EVs 246 
compared to healthy controls84. Similarly, another microfluidic-based platform was used to show 247 
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that the number of EpCAM+ EVs is correlated with disease progression in OC85. In another study, 248 
soluble E-cadherin was found to be released with EVs into ascitic fluid and the levels were able to 249 
distinguish between OC and benign disease86. Taken together, these results suggest that vesicular 250 
proteins have promising potential as biomarkers and that they could be potentially used as point 251 
of care testing (POCT) as quick, cheap and sensitive technique that could help to overcame the 252 
challenges related with early diagnosis.  253 
 254 
Other EV-associated molecules can also be used as biomarkers. A recent study published by Lea et 255 
al developed an ELISA assay that can detect and bind picogram-levels of phosphatidylserine (PS)-256 
containing EVs from the plasma of OC patients, and, based on the difference in the number of PS-257 
positive EVs, it can differentiate between malignant and benign disease87. The use of single EV-258 
methods that can distinguish between subpopulations of vesicles may also be useful in identifying 259 
cancer-specific EVs88. In another study, microvesicle-associated tissue factor procoagulant activity 260 
was able to distinguish between plasma from OC patient and healthy controls89.  261 
 262 
Future perspective 263 
EVs are not the only potential source of non-invasive circulating biomarkers for detecting and 264 
monitoring cancer. In particular, the use of cell-free DNA, circulating tumour DNA and circulating 265 
tumour cells have shown both diagnostic and prognostic utility in the diagnosis and monitoring of 266 
OC90, 91.  267 
 268 
Although EVs have gained a lot of attention in recent years as a potential biomarker for OC and 269 
other cancer types, there is still much work required before their potential can be realised.  270 
 271 
There remain many challenges associated with working with EVs48, 50, 52. There are several 272 
methods for extracting EVs but no universal agreement on which technique is most appropriate 273 
for diagnostic purposes. The most commonly used techniques are ultracentrifugation (UC) and size 274 
exclusion chromatography (SEC), but both of these approaches lead to the enrichment of EVs with 275 
different biofluid impurities including soluble proteins and lipoproteins. Combining 276 
methodologies, such as SEC and density cushion centrifugation can help to remove lipoproteins 277 
and therefore improve EV purity52, 92. Antibody-bound magnetic beads that are specific to EV 278 
markers such as CD63 can be used to isolate vesicles and enhance purity92. Methods that rely on 279 
polyethylene glycol-based precipitation result in much lower EV purity but give higher yields93; 280 
miRNA/protein biomarkers discovered using such methods cannot be definitively attributed as 281 
vesicular (unless further validation is performed) but if the biomarker is reproducibly and robustly 282 
altered in OC then it has value. Microfluidic approaches for EV isolation are being developed that 283 
can be combined with novel sensor technologies81, 84, 85; these approaches may be less useful for 284 
biomarker discovery (due to the smaller scale of material that they produce) but could be used 285 
effectively to detect differences in specific EV cargo in ovarian cancer patients. Further research is 286 
needed to develop isolation and detection technology, and to assess the effect of isolation 287 
methodology on EV purity.  288 
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 289 
Purifying EVs from different biofluids presents various challenges94, and there are many pre-290 
analytical variables that can affect the measurement of biomarkers such as vesicular miRNA and 291 
proteins51. These include the method of biofluid collection, time of day, whether the patient has 292 
fasted and the presence of other conditions. These factors could affect biomarker discovery and 293 
the testing of biomarkers in a clinical setting. More work is therefore required to establish the 294 
effect of pre-analytical variables on the detection of EV cargo and robust procedures must be put 295 
in place for diagnostic applications.  296 
 297 
Another challenge to quantifying EV cargo is choosing the most appropriate ‘reference gene’. It is 298 
not clear, at present, which proteins or RNAs are most appropriate as a reference for 299 
normalisation. The normalisation of expression of RNAs or proteins of interest can therefore be 300 
problematic, with outcomes depending on the choice of reference. More studies are needed to 301 
identify EV content whose levels are the most stable in different conditions and between different 302 
individuals.  303 
 304 
EVs in any given biofluid are released from a variety of cells. A tumour may contribute EVs to this 305 
heterogeneous population, and the proportion of tumour-derived vesicles will increase as the 306 
disease progresses. The ability to detect a smaller number of cancer EVs in this sea of normal EVs 307 
depends on several factors, including the nature of extraction methodology, the sensitivity of the 308 
detection assay and the ‘normal levels’ of the EV-cargo being measured. In the ideal test, the EV-309 
cargo being detected would be absent in normal biofluid but present in high levels after the 310 
appearance of a tumour. The test could be run on a small amount of biofluid at the point-of-care 311 
and be sufficiently sensitive to pick up very small numbers of cancer-derived EVs. As the sensitivity 312 
of EV-based detection methods increase it may be possible to move beyond the use of a test to 313 
monitor treatment/relapse towards a true diagnostic test for early-stage OC in asymptomatic 314 
individuals. Ideally, the collection of this biofluid would be minimally invasive for the patients and 315 
part of their routine disease follow-up (such as blood collection, for example). Whilst 316 
improvements are being made in all these areas, this hypothetical test does not currently exist.  317 
Further work is necessary to identify novel potential biomarkers in EVs and develop the 318 
technology required to isolate and detect them. Exciting progress is being made in this area which 319 
we hope will allow us to unlock the potential of EVs for earlier diagnosis of ovarian cancer in the 320 
near future.  321 
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Figure1 – Illustration of biogenesis pathways for EVs.  Microvesicles (MVs) are directly released by 645 
outward budding of the plasma membrane. The precursors for exosomes are formed inside 646 
multivesicular bodies (MVBs) as intraluminal vesicles (ILVs). MVBs can fuse with the lysosomes 647 
leading to the degradation of their content or fuse with the PM leading to the release of exosomes 648 
into the extracellular space. Exosomes can then be taken up by recipient cells through different 649 
pathways leading to the transfer of their cargo and potentially modifying the behavior of recipient 650 




Table1 – EV components identified in EOCs patients that could be used as potential biomarkers for 655 






Candidate Sample source Comment Reference 
Proteins CA125 Ascites Vesicular CA125 higher 
than circulating CA125 in 
early stage  
Peng P et al 
2011 77 
Claudin 4 Plasma and cell 
lines  
Abundant in EVs from 
plasma of OC patients in 
late stages (potential use 
in combination with 
CA125) 
Li J et al 2009 78 
TGFβ1 and MAGE3 Plasma Higher in plasma from 
OCs patients. Total EV-
protein concentration 
decreased in responsive 
patients after treatment 




Ascites and serum Ascites EVs correlates 
with  serum EV levels 
and carry late stage 
disease markers 
Keller S et al 
200980, Taylor D 
and Gercel-
Taylor 200868 
CD24 Ascites and cell 
lines 
High CD24 is associated 
with poor prognosis in 
OC and is released in 
tumour-derived EVs 
Runz S et al 
200782 
CD24 and EpCAM Ascites Expression is associated 
with chemotherapy 
response 
Im H et al 2014 
83 
EpCAM Serum EpCAM positive EVs 
increase in plasma of 
stage IV patients 
Hisey CL et al 
201885 
E-cadherin Ascites and non-
cancer ovarian 
cell line  
Can help distinguish 
between healthy and 
benign disease 
Tang MKS et al 
201886 
miRNA miR-21, miR-141, 
miR-200, miR-214 
Serum Levels of these miRNAs 
were similar in the EVs 
and tumour cells and 
were predictive of 
disease stage 




miR-200 a/b/c and 
miR-373 
Serum Higher levels in EOC 
patients. miR200 specific 
for malignant disease. 
miR200b/c higher in 
patients with stage III-IV 
disease and are 
associated with CA125 
level 
Meng X et al 
201667 
miR- 21, miR- 23b 
and miR- 29a  
Ascites and 
pleural effusion 
Associated with poor 
survival 








Serum Specific for early-stage. 
Most of these found in 
EVs 
Yokoi A et al 
201773 
miR-21 Ascites Up-regulated in 
malignant cells and 
tumour-derived EVs 
Cappellesso R 
et al 201474 
miR-200b and 
miR-320 
Plasma EV levels higher in stage 
IV patients. Both miRNA 
are higher in patients 
compared with healthy 
controls and they are 
positively correlated 
with CA125 
Pan C et al 
201875 
miR-30a-5p Urine Higher in urine of 
ovarian cancer patients, 
particularly in stage I 
and II 




Plasma and cell 
lines  
Higher in cancer-derived 
EVs 






Plasma Improved diagnostic 
benefit when combined 
with CA-125 levels 
Claussen C et al 
201689 
 659 
